HYPERION DEFI, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
HYPERION DEFI, INC. (HYPD) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 355.08 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-08-13
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-06-30 was 243.95K shares, a 58.82% increase year-over-year.
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-03-31 was 111.13K shares, a 53.70% decline year-over-year.
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-12-31 was 8.13K shares.
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-09-30 was 2.00M shares.
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 2.40M shares, a 52020.77% increase from fiscal 2024.
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 4.61K shares, a 95.65% decline from fiscal 2023.
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 106.02K shares, a 45.15% decline from fiscal 2022.
- HYPERION DEFI, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 193.30K shares, a 286.89% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 243.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 355.08K shares 10-Q · filed 2026-08-13 | 363.20K shares derived: sum of 3 quarters · filed 2026-08-13 | 2.36M shares derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | 111.13K shares 10-Q · filed 2026-05-15 | 119.26K shares derived: sum of 2 quarters · filed 2026-05-15 | 2.12M shares derived: sum of 3 quarters · filed 2026-05-15 | 2.27M shares derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-12-31 | 8.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 2.01M shares derived: sum of 2 quarters · filed 2026-03-30 | 2.16M shares derived: sum of 3 quarters · filed 2026-03-30 | 2.40M shares 10-K · filed 2026-03-30 | |
| 2025-09-30 | 2.00M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 2.15M shares derived: sum of 2 quarters · filed 2025-11-14 | 2.39M shares 10-Q · filed 2025-11-14 | 2.03M shares derived: sum of 4 quarters · filed 2025-11-14 | |
| 2025-06-30 | 153.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 393.60K shares 10-Q · filed 2025-08-13 | 29.32K shares derived: sum of 3 quarters · filed 2025-08-13 | 29.32K shares derived: sum of 4 quarters · filed 2025-08-13 | |
| 2025-03-31 | 240.00K shares 10-Q · filed 2025-05-19 | -124.28K shares derived: sum of 2 quarters · filed 2025-05-19 | -124.28K shares derived: sum of 3 quarters · filed 2025-05-19 | ||
| 2024-12-31 | -364.28K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -364.28K shares derived: sum of 2 quarters · filed 2025-04-15 | 4.61K shares 10-K · filed 2025-04-15 | ||
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 368.89K shares 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | 368.89K shares 10-Q · filed 2024-08-14 | ||||
| 2023-12-31 | 19.81K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | 19.81K shares derived: sum of 2 quarters · filed 2024-03-18 | 106.02K shares 10-K · filed 2024-03-18 | ||
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 86.20K shares 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | 86.20K shares 10-Q · filed 2023-08-11 | ||||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 61.69K shares derived: sum of 2 quarters · filed 2023-03-31 | 179.38K shares derived: sum of 3 quarters · filed 2023-03-31 | 193.30K shares 10-K · filed 2023-03-31 | |
| 2022-09-30 | 61.69K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 179.38K shares derived: sum of 2 quarters · filed 2022-11-14 | 193.30K shares 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | 117.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 131.61K shares 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 13.93K shares 10-Q · filed 2022-05-13 | ||||
| 2021-12-31 | 49.96K shares 10-K · filed 2022-03-30 | ||||
| 2018-07-24 | 20.16K shares 10-Q · filed 2018-11-13 | ||||
| 2017-12-31 | 61.88K shares 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |